Page 2 - CIMA SCS Workbook November 2018 - Day 1 Suggested Solutions

CIMA NOVEMBER 2018 – STRATEGIC CASE STUDY

12. What is the profit margin earned by 98.2% ((5.27-0.095)/5.27) – p.13
Novak on 1 tablet of Mintac?

13. Which projects (in general) might Projects of C$50m or more due to the difficulty of
Novak have difficulty in getting proving a viable market for the drug exists – p.23
finance for?

14. What is an “orphan disease”? Orphan diseases are defined as being rare,
affecting only a small proportion of any given
country’s population – p.26

15. What is the maximum period of 35 years: 20 years worldwide patent + 5 years
time for which a pharmaceuticals possible extended patent + up to 10 years
company might benefit from regulatory exclusivity – p.6
protection to its intellectual
property?

16. What can remain an important The trademarked name. Whilst a competitor might
source of competitive advantage to produce its own variant of a drug that is no longer
a pharmaceuticals company once its protected by patent, it cannot sell it under the
product has gone “off-patent”? trademarked name unless they purchase a licence
– p.7

17. What enables Novak to attract high It’s reputation as being highly innovative – p.11
quality research staff?

18. Does Novak manufacture products No – p.11
developed by other companies that
have gone “off-patent”?

19. By how much has Novak reduced its 26% - p.17
carbon emissions from
manufacturing activities over the
last 10 years?

20. How many people does Novak 108,000 – p.18
employ globally?

42 KAPLAN PUBLISHING